Inclusion Criteria:

- Patients >18 years affected by malignant pleural mesothelioma previously treated with
no more than one systemic therapeutic regimen

- Histologically or cytological confirmed malignant pleural mesothelioma of any of the
following subtype: epithelial, sarcomatous, mixed

- Prior intrapleural cytotoxic agents including bleomycin not considered systemic
chemotherapy

- ECOG Performance status 0 - 2

- Adequate baseline bone marrow, hepatic and renal function, defined as follows:

- Neutrophils > 1.5 x 10^9/L and platelets > 100 x 10^9/L

- Bilirubin < 1.5 x ULN

- AST and/or ALT < 2.5 x ULN in absence of liver metastasis

- AST and/or ALT < 5 x ULN in presence of liver metastasis

- Serum creatinine < 1.5 x ULN

- Absence of any conditions in which hypervolemia and its consequences (e.g. increased
stroke volume, elevated blood pressure) or haemodilution could represent a risk for
the patient (take as reference "Technical data sheet human albumin" specifically used
in Pharmacy Department for NGR-hTNF dilution)

- Patients may have had prior therapy providing the following conditions are met:

- Chemotherapy and radiotherapy: wash-out period of 28 days

- Surgery: wash-out period of 14 days

- Normal cardiac function and absence of uncontrolled hypertension

- Patients must give written informed consent to participate in the study

Exclusion Criteria:

- Concurrent anticancer therapy

- Patients may not receive any other investigational agents while on study

- Clinical signs of CNS involvement

- Patients with active or uncontrolled systemic disease/infections or with serious
illness or medical conditions, which is incompatible with the protocol

- Known hypersensitivity/allergic reaction to human albumin preparations or to any of
the excipients

- Any psychological, familial, sociological or geographical condition potentially
hampering compliance with the study protocol

- Pregnancy or lactation. Patients - both males and females - with reproductive
potential (i.e. menopausal for less than 1-year and not surgically sterilized) must
practice effective contraceptive measures throughout the study. Women of childbearing
potential must provide a negative pregnancy test (serum or urine) within 14 days
prior to registration